Rhesus macaque model for ovarian cancer chemoprevention

PURPOSE

The objective of the study reported here was to explore whether a nonhuman primate model could be developed for chemoprevention of ovarian cancer.

METHODS

An initial feasibility trial was done with three monkeys to determine tolerance for these drugs and for acquisition of surgical ovarian biopsy specimens. In the study, 19 female adult Macacca mulatta (rhesus macaques) were given fenretinide (4HPR) oral contraceptive (OCP), the combination of 4HPR+OCP, or no medication for three months. Laparotomy was performed before and after drug administration, and ovarian biopsy specimens were obtained to evaluate the potential for this animal as a model for ovarian cancer chemoprevention, as well as evaluating fluorescence spectroscopy and other potential biomarkers for ovarian cancer prevention studies.

RESULTS

The monkeys tolerated the drugs, surgeries, and acquisition of multiple ovarian biopsy specimens with resultant minimal morbidity. On initial data analysis, fluorescence spectroscopy was the marker that appeared the most promising.

CONCLUSIONS

On the basis of results of this study, this model merits further investigation. The rhesus monkey is an excellent candidate for a nonhuman primate model for ovarian cancer chemoprevention.

Prolactin response to buspirone was reduced in violent compared to nonviolent parolees

A neuroendocrine challenge procedure was carried out in male and female parolees. The parolees were divided into violent and non-violent groups based upon their criminal history. Buspirone (0.4 mg/kg), a 5-HT1a agonist, was used as the challenge agent and plasma prolactin levels were determined. The violent parolees had a blunted prolactin response compared to the non-violent parolees. While reduced serotonergic activity may account for this difference, the pharmacology of buspirone and control of prolactin release suggest a role for dopamine. A reduced serotonergic response would be consistent with a large body of data linking reduced serotonin function and aggressive behavior. While the mechanism is not definite, these data clearly provide evidence for an altered and blunted biological response in parolees with a history of violence.

Expression of the oxytocin and vasopressin genes in human and baboon gonadal tissues

A variety of molecular techniques were used to search human and baboon gonadal tissues for evidence of transcription of the genes for the peptide hormones oxytocin and vasopressin. Only a highly sensitive assay based on a modification of the polymerase chain reaction succeeded in detecting mRNA copies of the oxytocin gene in both human and baboon corpus luteum. Vasopressin gene transcription was not detected in human testis and corpus luteum and was found only once in four different experiments in baboon corpus luteum. Evidence for oxytocin gene transcription in the human testis was found in three of five experiments. The method employed and subsequent sequence analysis of the polymerase products verified the presence of oxytocin mRNA with normal hypothalamic-type exonic structure in primate corpus luteum. Nevertheless, the very low levels of mRNA present are unlikely to support other than local functions for the encoded nonapeptide hormones.

Retention of intrauterine fetal bone increases menstrual prostaglandins

Intrauterine retention of fetal bone is a rare complication of abortion that can cause secondary infertility by an unknown mechanism. We report such a case in which menstrual fluid prostanoids were measured to elucidate the possible pathophysiology. The pattern of prostanoid increases was similar to that seen in intrauterine device users.

Expression of the human relaxin gene in the corpus luteum of the menstrual cycle and in the prostate

DNA-RNA hybridization has been used to assess the presence of relaxin gene transcripts in human luteal tissues of pregnancy and the menstrual cycle, as well as in the human testis and prostate. The results imply a substantial capacity for hormone biosynthesis in the mid to late luteal phase of the ovary in non-pregnant women. In men the prostate has been shown also to express relaxin gene transcripts, though levels are low. The testis appears negative. The results suggest that functions for relaxin must be sought also outside pregnancy.

Hormones and cervical ripening: dehydroepiandrosterone sulfate, estradiol, estriol, and progesterone

Fetal adrenal steroids have been shown to be important in the timing of parturition. Since dehydroepiandrosterone sulfate is converted to estrogen, which is important in cervical softening, levels of dehydroepiandrosterone sulfate together with those of estradiol, estriol, and progesterone were measured and compared in pregnant women undergoing induction of labor with ripe and unripe uterine cervices. While there were no differences between the levels of estradiol, estriol and progesterone in the two groups of women, dehydroepiandrosterone sulfate was significantly elevated in the group of women with ripe cervices. These findings suggest that cervical changes preceding the onset of labor are associated with a significant elevation of maternal dehydroepiandrosterone sulfate levels. Changes in maternal plasma estradiol, estriol, and progesterone levels do not appear to be clinically related to cervical ripeness.

Alterations in reproductive tissue prostaglandins E and F, 6-keto-prostaglandin F1 alpha and thromboxane B2 with gestational age in the rat

Prostaglandins (PGs) are thought to have an important function in the initiation and/or propagation of parturition. To define the relationship of individual PGs to one another and compare their alterations with gestational age, PGF, PGE, 6-keto-PGF1 alpha (6KF) and thromboxane B2 (TxB2) were measured in uterine and placental tissue and uterine venous plasma of rats at Days 15, 18, 19, 20, and 21 of pregnancy and at delivery (Day 21 1/2). In addition, concomitant measurements of peripheral plasma estradiol (E2), estrone (E1) and progesterone (P) and pituitary oxytocin (OT) content, putative regulators and/or modulators of PG metabolism, were determined. Significant enhancements (P less than 0.05) in uterine 6KF, TxB2, PGF and PGE concentrations (ng/mg DNA) were detected by Day 20 compared to Day 15 of pregnancy and further dramatic increases were found on Day 21 and at delivery. Although uterine 6KF was present in the highest concentrations, PGF showed the greatest increment from Day 15 to delivery. No alterations in uterine venous plasma PGE or PGF concentration were found with gestational age but 6KF and TxB2 showed significant increases at delivery. The placental concentrations of PGs were approximately 1/50 of uterine tissue. Placental PGE and PGF concentrations (ng/mg DNA) increased only slightly at delivery but the augmentation in 6KF and TxB2 levels were of greater magnitude. Significant increases in E2 and E1 with reciprocal decreases in P occurred on Day 21 of pregnancy. In contrast, pituitary OT content showed no alterations at any of the days examined. These results are consonant with the hypothesis that uterine PGs have an important function in parturition and uterine-placental physiology, and suggest that an increasing estrogen/P ratio at the end of pregnancy is related to enhanced uterine PG levels.